Skip to main content
Log in

Hepatitis C therapies

  • From the Analyst's Couch
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1: Evolution of HCV therapy.

References

  1. Strader, D. B. et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 39, 1147–1171 (2004).

    Article  Google Scholar 

  2. Jensen, D. M. & Ascione, A. Future directions in therapy for chronic hepatitis C. Antivir. Ther. 13 (Suppl. 1), 31–36 (2008).

    CAS  PubMed  Google Scholar 

  3. Vertex. Vertex Reports 52% SVR 12 Rate for a 24-week Telaprevir-based Regimen in Genotype 1 Hepatitis C Patients Who Failed Prior Treatment. Vertex web site [online], (2008).

  4. HIV and Hepatitis.com. R7128 Demonstrates Potent Anti-HCV Activity in Combination with Pegylated Interferon/Ribavirin; Ongoing Trial to be Expanded. HIV and Hepatitis.com web site [online], (2008).

  5. Modi, A. A. & Hoofnagle, J. H. New therapies for hepatitis C. Hepatology 46, 615–617 (2007).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Related links

Related links

FURTHER INFORMATION

Clinical trials.gov

Medline Plus Health Topics Hepatitis C

Rights and permissions

Reprints and permissions

About this article

Cite this article

Melnikova, I. Hepatitis C therapies. Nat Rev Drug Discov 7, 799–800 (2008). https://doi.org/10.1038/nrd2661

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2661

  • Springer Nature Limited

This article is cited by

Navigation